[Remote] Director, Pathology Services at Natera

United States

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

MD/DO degree and ABP board-certified/eligible in AP/CP and Molecular Pathology

Responsibilities

Clinical oversight of Natera’s laboratory pathology testing
Ensure accurate and reliable patient test results
Proper maintenance of the histology lab for FFPE tissue block processing, slide staining/coverslipping/scanning, and performance evaluation of other pathologists
Review patient specimens prior to testing in collaboration with other stakeholders
Review clinical notes and pathology reports for tumor information and perform tumor circling on H&E slides
Review and sign out of Immunohistochemistry reports
Provide clinical and technical support for genetic counselors and other laboratory personnel
Set standards for laboratory testing and acceptable levels of analytic performance
Analyze lab data and contribute to or write publications for scientific journals
Serve as Clinical Consultant, ensuring proper utility of assays, test appropriateness, and pertinent information in test reports
Serve as Technical Supervisor, ensuring appropriate test method selection, method verification, proficiency testing enrollment, and quality assessment
Manage a team, including reviewing and approving assigned work, mentoring, and developing personnel
Maintain current status on Natera training requirements
Complete HIPAA/PHI privacy, General Policies and Procedure Compliance training, and security training within the first 30 days of hire

Skills

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free